ReviewExploration (Beijing, China)2025
A review of Mpox: Biological characteristics, epidemiology, clinical features, diagnosis, treatment, and prevention strategies.
Review in Exploration (Beijing, China), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Decoding sequence recognition code of nucleic acid-binding proteins of human-infecting DNA viruses.iMeta · 2026Article
- Overcoming Transmission Barriers: A Dual-Functional Adhesive Hydrogel for Direct Monkeypox Virus Neutralization and Wound Healing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Antifolate agent aminopterin demonstrates potent anti-monkeypox virus activityMicrobiology spectrum · 2026Article
- Tandem triplicate A29L peptide elicits robust immune responses against monkeypox virus in mice.Applied microbiology and biotechnology · 2026Article
- Therapeutic Innovations for Monkeypox Inhibition.International journal of molecular sciences · 2026Review
- MPOX transmission risks and biosafety protocols in laboratory animal research.Laboratory animal research · 2026Review
- Review
- Article
- Design of MOFs-based spatially confined catalysis-driven intelligent responsive photoacoustic probe for deep-tissue HMikrochimica acta · 2025Article
- Immunoinformatics-based strategies for developing DNA and mRNA vaccines against monkeypox virus (MPXV).Virology journal · 2025Article
- Role of Genomic, Economic, and Demographic Disparities in Mpox Epidemic in Africa: A Retrospective Cross-Country Analysis.Microorganisms · 2025Article
- Emerging strategies for monkeypox: antigen and antibody applications in diagnostics, vaccines, and treatments.Military Medical Research · 2025Review
- A Compartmental Mathematical Model to Assess the Impact of Vaccination, Isolation, and Key Epidemiological Parameters on Mpox Control.Medical sciences (Basel, Switzerland) · 2025Article
- Comprehensive Genomic, Mutation, Phylogenetic, and Statistical Analysis of the Monkeypox Virus Across Multiple Countries.Indian journal of microbiology · 2025Article
- A review of Mpox: Biological characteristics, epidemiology, clinical features, diagnosis, treatment, and prevention strategies.Exploration (Beijing, China) · 2025Review
- Current status of next-generation vaccines against mpox virus: a scoping review.Frontiers in pharmacology · 2025Review
- The evolving mpox threat (2022-2024): clade dynamics, immune evasion, and escalating global health challenges.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The outbreak of monkeypox virus (MPXV) was declared a Public Health Emergency of International Concern (PHEIC) by the World Health Organization (WHO), and the zoonotic disease caused by viral infection was renamed as "Mpox" on November 28, 2022. Currently, there is no approved vaccine or specific antiviral treatment for Mpox, and a main preventive strategy against MPXV infection remains the smallpox vaccine. Although there was an emergency use authorization (EUA) of Brincidofovir and Tecovirimat for the clinical treatment of clade II Mpox, while Tecovirimat failed to reduce the duration of Mpox lesions among patients infected with clade I Mpox in the Democratic Republic of the Congo (DRC). Therefore, it is still an urgent need to develop an effective medication. This review aims to enhance the understanding of Mpox and contribute to its prevention and treatment strategies, it provides a systemic introduction of the biological and epidemiological characteristics of MPXV, the clinical feature and diagnosis of Mpox, as well as treatment and prevention strategies, which will improve the comprehension about MPXV and offer potential strategies for clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.